Last reviewed · How we verify
Fibrinolytic once daily
Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi.
Fibrinolytic agents dissolve blood clots by activating plasminogen to plasmin, which breaks down fibrin in thrombi. Used for Acute myocardial infarction, Acute ischemic stroke, Pulmonary embolism.
At a glance
| Generic name | Fibrinolytic once daily |
|---|---|
| Also known as | once daily lytics, tPA once daily |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Fibrinolytic agent / Thrombolytic |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fibrinolytic drugs work by converting the inactive zymogen plasminogen into its active form, plasmin, a serine protease that degrades fibrin—the structural protein that stabilizes blood clots. This mechanism enables dissolution of existing thrombi in conditions such as acute myocardial infarction, acute ischemic stroke, and pulmonary embolism. Once-daily formulation suggests a modified-release or long-acting variant designed to improve dosing convenience.
Approved indications
- Acute myocardial infarction
- Acute ischemic stroke
- Pulmonary embolism
Common side effects
- Bleeding / Hemorrhage
- Intracranial hemorrhage
- Allergic reaction
- Hypotension
Key clinical trials
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) (PHASE2)
- Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (PHASE4)
- STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction (PHASE4)
- A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions (PHASE2)
- Management of Pleural Space Infections (PHASE4)
- Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR (PHASE2)
- Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy (PHASE4)
- Platelet Hyperreactivity to Aspirin and Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrinolytic once daily CI brief — competitive landscape report
- Fibrinolytic once daily updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI